Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 29 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

24%

7 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

10 recruiting

Enrollment Performance

Analytics

Phase 1
13(44.8%)
Phase 2
8(27.6%)
Phase 3
7(24.1%)
N/A
1(3.4%)
29Total
Phase 1(13)
Phase 2(8)
Phase 3(7)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials
NCT07417553Phase 2Recruiting

A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis

Role: lead

NCT07388680Phase 2Recruiting

Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia

Role: lead

NCT07364448Phase 2Recruiting

A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis

Role: lead

NCT07343778Phase 3Recruiting

A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis

Role: lead

NCT07263152Phase 1Completed

QTc Assessment in a Single-Dose Study of Hydronidone Capsules

Role: lead

NCT07471217Phase 1Not Yet Recruiting

[¹⁴C] Hydronidone Mass Balance Study

Role: lead

NCT06899815Phase 1Recruiting

Preliminary Human Trials of F230 Tablets

Role: lead

NCT07412236Phase 3Not Yet Recruiting

A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.

Role: lead

NCT07394309Phase 1Not Yet Recruiting

Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls

Role: lead

NCT07262333Phase 1Recruiting

A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency

Role: lead

NCT07295873Phase 1Not Yet Recruiting

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide

Role: lead

NCT07262346Phase 1Not Yet Recruiting

The Phase Ⅰd Clinical Trial of Hydronidone Capsules

Role: lead

NCT05288179Phase 3Recruiting

Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis

Role: lead

NCT05689645Phase 2Recruiting

F573 for Injection for the Treatment of Liver Injury/Failure

Role: lead

NCT05704166Phase 2Recruiting

PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients

Role: collaborator

NCT05905172Phase 3Recruiting

Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

Role: lead

NCT03902509Phase 2Completed

A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

Role: lead

NCT05115942Phase 3Completed

Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

Role: lead

NCT05531955Phase 2Unknown

Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction

Role: collaborator

NCT04820049Phase 1Completed

F573 Ia Clinical Trial

Role: lead